Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NTLA with free AI briefings, catalyst countdowns, and dilution alerts.

NTLA · Intellia Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$614.8M Cash on Hand
21.9mo Cash Runway
39.8% Short Interest
$22.78 Analyst Target (18)
Follow NTLA by email Get an email when NTLA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NTLA, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-03-10 lonvoguran ziclumeran hereditary angioedema BLA 64% ±43% by Apr 16

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What NTLA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Lipid Nanoparticle Encapsulating mRNA Encoding… Neuromuscular Disease Phase 3 · NCT06672237 Active not recruiting
NTLA-2002 Hereditary Angioedema Phase 3 · NCT06634420 Active not recruiting
Biological NTLA-2002 Hereditary Angioedema Phase 1/2 · NCT05120830 Active not recruiting
Biological NTLA-3001 Lung Disease Phase 1/2 · NCT06622668 Withdrawn
LNP1265 Hemophilia B Phase 1/2 · NCT06379789 Recruiting
REGV131 Hemophilia B Phase 1/2 · NCT06379789 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NTLA holds $614.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $84.3M/quarter from operations, an estimated runway of 21.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NTLA files for a raise →

👥 Who Owns NTLA

Insiders 1.9% Institutions (425 holders) 97% Public and other holders 1.1%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 16,035,423 11.42% 2026-09-30
ARK Investment Management LLC Institution (13G, 5%+) 14,207,324 10.12% 2025-12-31
STATE STREET CORPORATION Institution (13G, 5%+) 7,809,060 5.56% 2026-09-30
Vanguard Portfolio Management Institution (13G, 5%+) 6,266,007 4.46% 2026-03-31
Shaw D.E. & Co., Inc. Institution (13F) 6,064,717 4.32% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 5,945,571 4.24% 2026-03-31
Two Sigma Investments, LP Institution (13F) 4,710,709 3.36% 2026-09-30
FMR, LLC Institution (13F) 4,692,148 3.34% 2026-09-30
Regeneron Pharmaceuticals Inc Institution (13F) 3,702,995 2.64% 2026-09-30
Amova Asset Management Americas Inc Institution (13F) 3,610,687 2.57% 2026-09-30
John M Leonard
President and CEO, Director · +225,400 options
Insider 1,196,479 0.85% 2026-11-02
Fred E Cohen
Director · +13,300 options
Insider 216,653 0.15% 2026-06-09

Share count 140,358,512 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-02
filed 2026-11-03
LEONARD JOHN M
Sale (S) 9,000 $11.99 1,138,064
2026-10-26
filed 2026-10-28
Marantz Jing L.
Award (A) 199,822 – 199,822
2026-10-26
filed 2026-10-28
Marantz Jing L.
Option award (A) 275,061 – –
2026-10-02
filed 2026-10-06
Dube Michael P
Sale (S) 1,864 $12.43 65,022
2026-08-21
filed 2026-08-24
LEONARD JOHN M
Sale (S) 2,785 $13.00 1,147,064

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full NTLA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NTLA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.